ArticleJACC. Case reports2026
Acquired Hemophilia A During Prasugrel Therapy After Recurrent Acute Coronary Syndrome.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of Bleeding Disorder During Dual Antiplatelet Therapy.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcquired hemophilia A (AHA), a rare autoimmune bleeding disorder caused by factor VIII inhibitors, may be overlooked in patients receiving antiplatelet therapies. CASE SUMMARY: A 60-year-old woman underwent percutaneous coronary intervention for non-ST-segment elevation myocardial infarction, receiving aspirin and prasugrel. After recurrent unstable angina, repeat percutaneous coronary intervention was performed, and dual antiplatelet therapy (DAPT) was resumed. One month later, she developed diffuse ecchymoses and progressive anemia. Investigations indicated AHA with isolated activated partial thromboplastin time (APTT) prolongation, reduced factor VIII activity, and factor VIII inhibitor positivity. DAPT was discontinued, and high-dose corticosteroid was initiated, causing complete remission; aspirin monotherapy was restarted. Unstable angina recurred, and coronary artery bypass grafting was performed. DISCUSSION: Unexplained bleeding with isolated APTT prolongation on DAPT should prompt evaluation for AHA and early hematology consultation. TAKE-HOME MESSAGE: Recognize AHA early; stop DAPT when safe, and favor revascularization strategies that minimize prolonged DAPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.